Articles tagged with Cancer Patients
The study found that BRAF alterations, particularly Class I mutations like v600E, are associated with improved overall survival in adults with glioma. However, the effectiveness of targeted therapies depends on the specific type and combination of genetic alterations driving the cancer.
The NCI-MATCH precision medicine cancer trial found a promising signal for the AKT inhibitor ipatasertib, meeting its primary endpoint with a 22% response rate in patients with rare AKT1 E17K tumor gene mutations. The study demonstrated clinically significant activity in patients, warranting additional studies.
Researchers found that liquid biopsies can detect clonal haematopoiesis, a condition placing patients at higher risk of developing myelodysplastic syndrome or acute myeloid leukaemia. The study suggests that these patients should be referred for further evaluation to uncover actual risk and identify potential diagnostic pathways.
A new study finds that combining radiation with hormone therapy can improve outcomes for patients with oligometastatic prostate cancer. The trial showed that patients who received both treatments experienced longer progression-free survival and better testosterone levels after treatment.
A recent study found that patients treated with the combination of chemoradiation therapy and immunotherapy in a phase 3 clinical trial did not experience significant safety concerns. The treatment regimen showed no significant increase in toxicity compared to standard trimodality therapy alone.
Researchers developed an AI model that uses daily step counts to predict the likelihood of unplanned hospitalization during cancer therapy, offering personalized care and potential prevention of treatment interruptions. The model was tested on data from wearable consumer devices and showed strong predictive performance.
Adding stereotactic body radiation therapy (SBRT) to sorafenib significantly improves overall survival, progression-free survival, and time to tumor progression in patients with advanced hepatocellular carcinoma. SBRT was shown to be effective without increasing toxicity.
A Phase III trial found that hypo-fractionated whole breast irradiation (WBI) with concurrent boost is not inferior to conventional WBI with a sequential boost following lumpectomy in patients with high-risk, early-stage breast cancer. The study showed comparable effectiveness and toxicity outcomes between the two treatment options.
A randomized phase III trial shows that adding radiation therapy to systemic therapy can delay tumor progression and lengthen survival without compromising quality of life. The combination of SBRT and sorafenib appears more effective than the drug on its own.
A randomized phase III trial found that hypofractionated whole-breast radiation with concurrent boost is comparable to six weeks of treatment for patients with higher-risk disease, reducing tumor recurrence by 20-30%. The three-week course was non-inferior to the longer treatment in terms of tumor recurrence and cosmetic outcomes.
The Canadian Medical Association Journal (CMAJ) publishes special issues on the impact of anti-Black racism on patient health and healthcare professionals. Research by Black health scholars and practitioners sheds light on systemic inequities, including cancer care disparities and gaslighting in academic medicine.
A novel algorithm uses near-infrared spectroscopy to estimate intracranial pressure (ICP) based on hemoglobin levels. The research validates the accuracy of this method using invasive ICP data.
The NRG-HN004 trial found that radiotherapy with durvalumab did not improve progression-free survival or overall survival compared to cetuximab in patients with locoregionally advanced head and neck squamous cell carcinoma who have a contraindication to cisplatin. The study highlighted the need for further research in this population.
A large clinical trial data analysis found that rates of locoregional recurrence are low regardless of regional node irradiation use. The study suggests a randomized clinical trial is required to answer the question of whether favorable-risk patients can safely skip RNI.
A large-scale analysis of VA medical centers found that facilities with lower yearly PSA screening rates had higher rates of metastatic prostate cancer in subsequent years. The study supports the benefits of prostate cancer screening in reducing metastatic prostate cancer risk, particularly for high-risk groups like Black patients.
In a first-in-human trial, FLASH radiation treatment was found safe and effective for pain relief in patients with bone metastases. The study showed significant pain relief in 7 out of 10 patients, with minimal side effects.
A phase II trial suggests that radiation can reduce painful complications and hospitalizations, and possibly extend overall survival in patients with advanced cancers. The study found that treating asymptomatic lesions with radiation reduced skeletal-related events and extended overall survival compared to those who received no radiation.
A randomized, phase III clinical trial found that patients who receive technical explanations from medical physicists before treatment have lower anxiety levels and higher satisfaction rates. Medical physicist consults can significantly improve patient outcomes by reducing stress and anxiety related to radiation therapy.
A phase III clinical trial confirms the safety and efficacy of a moderately shortened course of radiation therapy for men with high-risk prostate cancer. The study found no significant differences in survival rates, side effects, or recurrence between 5-week and 8-week radiation therapy.
A new study found that sexual side effects of cancer treatment are discussed less frequently with female patients, who are asked about their sexual health 1 in 10 times, compared to 9 in 10 men. The disparity is also observed in clinical trials nationwide.
Researchers have identified two distinct molecular subgroups of cervical cancer, C1 and C2, which differ in their clinical aggressiveness and response to treatment. The study suggests that determining the subgroup of a patient's cervical cancer could provide additional prognostic information for planning treatment.
A meta-analysis of 410 articles from 68 countries found that patients in lower-income countries take up to four times longer to initiate care for cancer treatment. Cancers causing non-specific symptoms, such as myeloma and colorectal cancer, typically take the longest to diagnose.
USC Norris Comprehensive Cancer Center is partnering with the Chinatown Service Center to address disparities in cervical cancer screening and treatment. The partnership aims to optimize access, shorten diagnosis-to-treatment timeframes, and enhance quality of care for Chinese and Latina women in Los Angeles.
Researchers have designed a potential therapeutic that dampens the activity of regulatory T cells, which can prevent the immune system from unleashing its full potential against tumor cells. The molecule, known as FOX3P, acts as a transcription factor for many Treg genes but isn't vital for other types of T cells.
A study published in JACC: CardioOncology found that exercise during chemotherapy improves long-term cardiorespiratory fitness and alleviates adverse effects of cancer treatment. After treatment, an exercise program can recover lost function. The optimal timing of exercise intervention is during chemotherapy.
A gene signature of four specific genes (SAA1, SAA2, APOL1, and MET) predicts the risk of tumour spreading and survival in kidney cancer patients. The study identified a link between the microenvironment and immune system inhibition.
Researchers analyzed 408 patients receiving immune checkpoint inhibitor therapy and found no increased risk of side effects from receiving both immunotherapy and the vaccine. The study supports NCCN's recommendations for COVID-19 vaccination in people with cancer, citing strong protection against severe COVID-19 for all variants.
Researchers at Mount Sinai's Tisch Cancer Institute have discovered a new gene, PDZK1IP1, essential to colon cancer growth. The study found that surrounding inflammation activates the super enhancer, promoting tumor cell survival and growth.
Researchers have identified a key enzyme in muscle that contributes to cancer-induced muscle wasting. Targeting this enzyme, UBR2, may help preserve muscle mass and function in cancer patients. The study's findings offer new hope for the treatment of cancer cachexia, a complication affecting 60% of all cancer patients.
A new therapy has been discovered to overcome treatment resistance in aggressive breast cancer by targeting fibroblasts and enhancing the immune response. The therapy, FAP-IL2v, binds to fibroblast-expressed molecules, allowing the immune system to break through the tumor's protective microenvironment and eliminate cancer cells.
A large multi-center study analyzing patient records from three major cancer centers found that ILC is detected later and has worse outcomes than IDC. The research highlights the need for new imaging technologies to improve early detection of ILC, which often spreads beyond breast tissue before diagnosis.
A recent study published in JMIR Cancer found that unvaccinated adult cancer patients with COVID-19 were seven times more likely to die from any cause of death compared to those without the infection. The study, conducted by researchers at Regenstrief Institute, analyzed data on adult cancer patients diagnosed between 2019 and 2020.
A new platform developed at Dana-Farber Cancer Institute helps match patients with cancer to trials of targeted therapy by analyzing genomic alterations in their tumors. The platform, called MatchMiner, has been shown to expedite the process of finding an appropriate trial for patients, reducing the time to consent by 22%.
A Singapore research team has validated a cancer diagnostic assay designed with Asian-centric biomarkers, showing high precision and sensitivity in measuring four major classes of biomarkers. The assay's performance was validated with clinical specimens, indicating its promise for reliable deployment in a clinical setting.
The study analyzed DNA methylation in skin tumor samples, revealing correlations between changes in proteins regulating the organism and prognosis. The results identified potential markers of patient survival and suggested a new route for understanding melanoma subtypes.
Interdisciplinary researchers at the Beckman Institute have received a four-year, $2M award from the National Institutes of Health to develop a device that can instantly enable real-time 3D ultrasound imaging. The device, named FASTER, is designed to improve high-quality medical imaging accessibility in diverse communities.
The American College of Physicians recommends increasing funding for health services and prioritizing health promotion in Indigenous communities. Community-driven public policy is also necessary to address historical trauma, social determinants of health, and inadequate access to healthcare services.
A Mediterranean diet rich in fibre, mono-unsaturated fatty acids and polyphenols has been associated with improved immunotherapy response rates and progression-free survival in advanced melanoma patients. The diet was also found to reduce the likelihood of drug-induced immune-related side effects.
Coskun's team has developed SpatialVizScore, a new method that visualizes tumor immunology in cancer tissues to identify patients more likely to respond to immunotherapy. The system looks at the interactions of multiple immune cells, including macrophages with subtypes M1 and M2.
A new genetic test called PancreaSeq accurately classifies pancreatic cysts as potentially cancerous or benign, improving the accuracy of diagnoses compared to current guidelines. The test distinguishes between different types of cysts with higher accuracy than traditional forms of surveillance and current pancreatic cyst guidelines.
A new epigenetics drug, tazemetostat, has been found to stop bladder cancer growth by activating the immune system, not just inhibiting tumors. The drug targets the EZH2 gene and is being tested in clinical trials for late-stage bladder cancer.
Moffitt researchers found that cancer patients who believed in vaccine effectiveness and safety were more likely to accept COVID-19 vaccination. High accepters were also more socioeconomically disadvantaged and lived with others, highlighting the need for targeted interventions.
A long-term study of over 300 breast cancer survivors found a link between chronic inflammation and cognitive problems. Higher levels of CRP were related to lower reported cognitive function, suggesting that this common test for inflammation may also indicate risk for cognitive concerns.
A recent study published in Acta Oncologica found that young women who have had cancer are at a higher risk of experiencing sexual problems, including loss of libido and intimacy issues. The study, which surveyed nearly 700 women, suggests that the type and intensity of cancer treatment can influence a patient's sex life.
A recent study found that cancer biomarker data is biased towards European populations, potentially misclassifying patients of Asian or African descent. The researchers propose a computational approach to correct this bias, which could have significant implications for treatment selection.
Scientists have identified a protein that regulates cancer cell spread and normal tissue cell shedding, potentially leading to new treatments. The research suggests that metastasis is not an abnormal process limited to cancer but a normal process used by healthy cells.
Researchers have developed a new approach to test the efficacy of multiple anticancer drug combinations simultaneously, rapidly, and accurately. Combi-seq overcomes limitations of conventional technologies by using microfluidics to carry out large-scale experiments with small sample volumes.
Researchers identified a specific gut bacterium responsible for antibiotic-induced GVHD after stem cell transplants. A sugar supplement was found to improve gut health by distracting the bacteria from attacking mucin in the intestinal lining, reducing complications such as GVHD.
A novel PET radiotracer has been developed to assess tumor aggressiveness in neuroendocrine neoplasms, providing valuable information for personalized care. High uPAR expression was associated with a worse prognosis, making it a potential target for therapy.
A USC-led team has found indications for an early breast cancer detection method using high-definition liquid biopsies. The test detected multiple cancer biomarkers, including 'oncosomes,' in the blood samples of most early-stage breast cancer patients.
A new predictive biomarker, RNF43 mutations, has been identified as a significant predictor of response to anti-BRAF/EGFR combinatory therapy in patients with microsatellite stable BRAF V600E metastatic colorectal cancer. This biomarker is associated with improved progression-free and overall survival rates.
Researchers are studying the interaction between obesity and nitric oxide synthase in triple-negative breast cancer, aiming to develop a new treatment strategy. Another team is investigating the role of NHE6 protein in multiple myeloma resistance to daratumumab treatment, with the goal of improving therapy outcomes for patients.
The NCCN Annual Congress on Hematologic Malignancies will address key findings on chronic lymphocytic leukemia management and CAR T-cells in diffuse large B-cell lymphoma. The event also features updates on immunotherapies in multiple myeloma treatment.
The Leducq Foundation has awarded $7.5 million to UVA researchers, led by Mete Civelek, to investigate sex differences in atherosclerosis and $8 million to Coleen McNamara to advance immunotherapy for cardiovascular disease. These projects aim to improve understanding of heart disease and develop new treatments.
The TTUHSC team will provide no-cost colorectal cancer screening and colonoscopies to underinsured and uninsured people living in South Plains region counties. The FIT-STOP program aims to find signs of early-stage colorectal cancer to prevent treatment needs, leveraging existing relationships with partners.
Researchers at the University of Helsinki have identified target genes of the MYC oncogene responsible for its growth-promoting effects. By modifying these genomic binding sites, they slowed down cell growth. This finding has significant implications for developing new cancer treatments.
UCF researchers have designed a cerium oxide nanoparticle to protect bones against radiation damage from cancer therapy. The treatment also improves bone regeneration and kills cancer cells, reducing the risk of bone fractures and tissue damage.
A potential new treatment for glioblastomas, a deadly form of brain tumor, is being researched using the medication letrozole. Studies have shown that letrozole can be effective in killing tumor cells and reaching target tissue safely.
A recent study supports fourth vaccination for cancer patients to protect them against COVID-19. Patients with solid tumours and hematological cancers showed a significant increase in antibody levels after a fourth dose of one of the currently approved vaccines.
Researchers at UVA Health System have made a groundbreaking discovery that could boost platelet production on demand to alleviate blood shortages. The finding offers hope for patients with thrombocytopenia and those receiving cord-blood transplants.